1123 related articles for article (PubMed ID: 22044434)
1. Good quality white-light transurethral resection of bladder tumours (GQ-WLTURBT) with experienced surgeons performing complete resections and obtaining detrusor muscle reduces early recurrence in new non-muscle-invasive bladder cancer: validation across time and place and recommendation for benchmarking.
Mariappan P; Finney SM; Head E; Somani BK; Zachou A; Smith G; Mishriki SF; N'Dow J; Grigor KM;
BJU Int; 2012 Jun; 109(11):1666-73. PubMed ID: 22044434
[TBL] [Abstract][Full Text] [Related]
2. Real-life Experience: Early Recurrence With Hexvix Photodynamic Diagnosis-assisted Transurethral Resection of Bladder Tumour vs Good-quality White Light TURBT in New Non-muscle-invasive Bladder Cancer.
Mariappan P; Rai B; El-Mokadem I; Anderson CH; Lee H; Stewart S; Donat R
Urology; 2015 Aug; 86(2):327-31. PubMed ID: 26142924
[TBL] [Abstract][Full Text] [Related]
3. The presence of detrusor muscle in the pathological specimen after transurethral resection of primary pT1 bladder tumors and its relationship to operator experience.
Rouprêt M; Yates DR; Varinot J; Phé V; Chartier-Kastler E; Bitker MO; Compérat E
Can J Urol; 2012 Oct; 19(5):6459-64. PubMed ID: 23040628
[TBL] [Abstract][Full Text] [Related]
4. Good quality white-light transurethral resection of bladder tumours (GQ-WLTURBT) with experienced surgeons performing complete resections and obtaining detrusor muscle reduces early recurrence in new non-muscle-invasive bladder cancer: validation across time and place and recommendation for benchmarking.
Yeo L; Jain S
BJU Int; 2012 Apr; 109(8):E27; author reply E27-8. PubMed ID: 22455408
[No Abstract] [Full Text] [Related]
5. Presence of detrusor muscle in bladder tumor specimens--predictors and effect on outcome as a measure of resection quality.
Shoshany O; Mano R; Margel D; Baniel J; Yossepowitch O
Urol Oncol; 2014 Jan; 32(1):40.e17-22. PubMed ID: 23911682
[TBL] [Abstract][Full Text] [Related]
6. Enhanced Quality and Effectiveness of Transurethral Resection of Bladder Tumour in Non-muscle-invasive Bladder Cancer: A Multicentre Real-world Experience from Scotland's Quality Performance Indicators Programme.
Mariappan P; Johnston A; Padovani L; Clark E; Trail M; Hamid S; Hollins G; Simpson H; Thomas BG; Hasan R; Bhatt J; Ahmad I; Nandwani GM; Mitchell IDC; Hendry D;
Eur Urol; 2020 Oct; 78(4):520-530. PubMed ID: 32690321
[TBL] [Abstract][Full Text] [Related]
7. The value of extended transurethral resection of bladder tumour (TURBT) in the treatment of bladder cancer.
Richterstetter M; Wullich B; Amann K; Haeberle L; Engehausen DG; Goebell PJ; Krause FS
BJU Int; 2012 Jul; 110(2 Pt 2):E76-9. PubMed ID: 22313727
[TBL] [Abstract][Full Text] [Related]
8. Detrusor muscle in the first, apparently complete transurethral resection of bladder tumour specimen is a surrogate marker of resection quality, predicts risk of early recurrence, and is dependent on operator experience.
Mariappan P; Zachou A; Grigor KM;
Eur Urol; 2010 May; 57(5):843-9. PubMed ID: 19524354
[TBL] [Abstract][Full Text] [Related]
9. Prospective randomized trial of hexylaminolevulinate photodynamic-assisted transurethral resection of bladder tumour (TURBT) plus single-shot intravesical mitomycin C vs conventional white-light TURBT plus mitomycin C in newly presenting non-muscle-invasive bladder cancer.
O'Brien T; Ray E; Chatterton K; Khan MS; Chandra A; Thomas K
BJU Int; 2013 Dec; 112(8):1096-104. PubMed ID: 24053153
[TBL] [Abstract][Full Text] [Related]
10. 'Real-life experience': recurrence rate at 3 years with Hexvix
Gallagher KM; Gray K; Anderson CH; Lee H; Stewart S; Donat R; Mariappan P
World J Urol; 2017 Dec; 35(12):1871-1877. PubMed ID: 28803385
[TBL] [Abstract][Full Text] [Related]
11. The significance of lymphovascular invasion in transurethral resection of bladder tumour and cystectomy specimens on the survival of patients with urothelial bladder cancer.
Streeper NM; Simons CM; Konety BR; Muirhead DM; Williams RD; O'Donnell MA; Joudi FN
BJU Int; 2009 Feb; 103(4):475-9. PubMed ID: 18990174
[TBL] [Abstract][Full Text] [Related]
12. Clinical and cost effectiveness of hexaminolevulinate-guided blue-light cystoscopy: evidence review and updated expert recommendations.
Witjes JA; Babjuk M; Gontero P; Jacqmin D; Karl A; Kruck S; Mariappan P; Palou Redorta J; Stenzl A; van Velthoven R; Zaak D
Eur Urol; 2014 Nov; 66(5):863-71. PubMed ID: 25001887
[TBL] [Abstract][Full Text] [Related]
13. Can re-cTURBT be useful in pT1HG disease as a risk indicator of recurrence and progression? A single centre experience.
Giulianelli R; Gentile BC; Mirabile G; Albanesi L; Tariciotti P; Rizzo G; Buscarini M; Vermiglio M
Arch Ital Urol Androl; 2017 Dec; 89(4):272-276. PubMed ID: 29473376
[TBL] [Abstract][Full Text] [Related]
14. Impact of transurethral resection of bladder tumor: analysis of cystectomy specimens to evaluate for residual tumor.
Lee SE; Jeong IG; Ku JH; Kwak C; Lee E; Jeong JS
Urology; 2004 May; 63(5):873-7; discussion 877. PubMed ID: 15134968
[TBL] [Abstract][Full Text] [Related]
15. [Impact of operator experience on TURB of high-grade non-muscle-invasive bladder cancer--analysis of 254 second resections at a university teaching hospital].
Lazica DA; Degener S; Böttcher S; Brandt AS; Störkel S; Roth S
Aktuelle Urol; 2013 May; 44(3):196-200. PubMed ID: 23712276
[TBL] [Abstract][Full Text] [Related]
16. Enhanced Visualization Methods for First Transurethral Resection of Bladder Tumour in Suspected Non-muscle-invasive Bladder Cancer: A Health Technology Assessment.
Ontario Health (Quality)
Ont Health Technol Assess Ser; 2021; 21(12):1-123. PubMed ID: 34484486
[TBL] [Abstract][Full Text] [Related]
17. Role of immediate radical cystectomy in the treatment of patients with residual T1 bladder cancer on restaging transurethral resection.
Sternberg IA; Keren Paz GE; Chen LY; Herr HW; Dalbagni G
BJU Int; 2013 Jul; 112(1):54-9. PubMed ID: 23146082
[TBL] [Abstract][Full Text] [Related]
18. Pathology-based risk stratification of muscle-invasive bladder cancer patients undergoing cystectomy for persistent disease after induction chemoradiotherapy in bladder-sparing approaches.
Koga F; Fujii Y; Masuda H; Numao N; Yokoyama M; Ishioka J; Saito K; Kawakami S; Kihara K
BJU Int; 2012 Sep; 110(6 Pt B):E203-8. PubMed ID: 22289431
[TBL] [Abstract][Full Text] [Related]
19. Time between first and second transurethral resection of bladder tumors in patients with high-grade T1 tumors: is it a risk factor for residual tumor detection?
Süer E; Özcan C; Baltacı S; Gülpınar Ö; Burgu B; Haliloğlu A; Bedük Y
Urol Int; 2013; 91(2):182-6. PubMed ID: 23751593
[TBL] [Abstract][Full Text] [Related]
20. Construction of predictive models for recurrence and progression in >1000 patients with non-muscle-invasive bladder cancer (NMIBC) from a single centre.
Ali-El-Dein B; Sooriakumaran P; Trinh QD; Barakat TS; Nabeeh A; Ibrahiem el-HI
BJU Int; 2013 Jun; 111(8):E331-41. PubMed ID: 23445082
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
